Arena Pharmaceuticals Investor Relations Material

Latest events

Q4 2021

23 Feb, 2022

Q4 2020

23 Feb, 2021
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Arena Pharmaceuticals Inc

Access all reports
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company offers BELVIQ, a serotonin 2C receptor agonist approved for marketing in the United States; Belviq XR, an extended-release formulation of lorcaserin; APD334 that is in phase II clinical study for treating autoimmune diseases, including ulcerative colitis and Crohn's disease; APD371 for the treatment of patients with pain associated with Crohn's disease; and APD811, which is in phase I clinical stage to treat pulmonary arterial hypertension. It also develops ralinepag (APD811), which has completed phase II clinical stage for the treatment of pulmonary arterial hypertension.